Both activating mutations, ALK-F1174L and ALK-R1275Q, were also shown to contribute to NB tumorigenesis in transgenic and knock-in (KI) animal models, as well as to cooperate with MYCN in the oncogenic process [23-26]. The gene discussed is MYCN; the disease is neuroblastoma.